Cargando…
Switching Between Adalimumab Reference Product and BI 695501 in Patients with Chronic Plaque Psoriasis (VOLTAIRE-X): A Randomized Controlled Trial
BACKGROUND: BI 695501 is an FDA-approved biosimilar to adalimumab reference product (RP). VOLTAIRE-X was a randomized clinical trial to assess outcomes with a biosimilar monoclonal antibody in line with the FDA requirements for designation as an ‘interchangeable’ biosimilar. OBJECTIVE: The aim of th...
Autores principales: | Menter, Alan, Cohen, Stanley, Kay, Jonathan, Strand, Vibeke, Gottlieb, Alice, Hanauer, Stephen, Eduru, Sravan Kumar, Buschke, Susanne, Lang, Benjamin, Liesenfeld, Karl-Heinz, Schaible, Jennifer, McCabe, Dorothy |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9464749/ https://www.ncbi.nlm.nih.gov/pubmed/35934770 http://dx.doi.org/10.1007/s40257-022-00708-w |
Ejemplares similares
-
Summary of Research: Switching Between Adalimumab Reference Product and BI 695501 in Patients with Chronic Plaque Psoriasis (VOLTAIRE-X): A Randomized Controlled Trial
por: Menter, Alan
Publicado: (2023) -
Similar Pharmacokinetics of the Adalimumab (Humira(®)) Biosimilar BI 695501 Whether Administered via Subcutaneous Autoinjector or Prefilled Syringe (VOLTAIRE(®)-AI and VOLTAIRE(®)-TAI): Phase 1, Randomized, Open-Label, Parallel-Group Trials
por: Ramael, Steven, et al.
Publicado: (2018) -
Similar efficacy, safety and immunogenicity of adalimumab biosimilar BI 695501 and Humira reference product in patients with moderately to severely active rheumatoid arthritis: results from the phase III randomised VOLTAIRE-RA equivalence study
por: Cohen, Stanley B, et al.
Publicado: (2018) -
Voltaire según Voltaire
por: Pomeau, René
Publicado: (1973) -
Visual Loss Induced by Adalimumab Used for Plaque Psoriasis
por: Saffra, Norman, et al.
Publicado: (2017)